Grants 2012
Fundamentele onderzoeksprojecten
Begunstigde
KULeuven
Duurtijd
(jaren)
4
Bedrag in
euro
312 000
UGent
UGent
4
4
187 000
320 000
4
360 000
Mechanisms regulating cancer stem cells during skin tumor initiation and
progression
Bollen Mathieu
ULB Erasme
KULeuven
4
260 000
Activation of protein phosphatase-1 as a novel cancer therapy
Breckpot Karin
Carmeliet Geert
Carmeliet Peter
VUB
KULeuven
KULeuven
4
2
4
232 000
160 000
360 000
Tri-ART2.0: Optimization of TriMix and Antigen RNA-based anti -cancer Therapy
Tumor cell metabolism contributes to the formation of micrometastases in bone
De Keersmaecker Kim
Dewerchin Mieke
Elewaut Dirk
Feron Olivier
KULeuven
KULeuven
UGent
UCL
4
4
4
4
320 000
260 000
245 000
280 000
Fuks François
ULBErasme
KULeuven
4
214 500
Role of ribosome defects in cancer
Endothelial glutamine metabolism: target for anti-tumor angiogenesis therapy?
In vivo visualization of NKT cell-mediated anti-tumor activity
Study of the determinants of the tumor metabolic plasticity in response to
fluctuating availabilities in the main energy fuels and oxygen : towards new
therapeutic strategies
Unravelling the epigenomic dimensions of breast cancers
4
360 000
UGent
3
165 000
Aerts Stein
Berx Geert
Beyaert Rudi
Blanpain Cédric
Gerhardt Holger
Haigh Jody
Instituut
Titel van het project
Identification of cancer driver mutations in the non-coding genome by integrative
genomics and regulome sequencing
EMT and inflammation: a malignant cocktail for cancer
Molecular and functional characterization of the tumor suppressors CYLD
and A20 as ubiquitin modulating enzymes
The role of PFKB3 in endothelial metabolism: can PFKFB3 become a novel anti-cancer
strategy?
Cellular and molecular mechanisms of vascular patterning in tumour angiogenesis:
mosaic
endothelial single cell analysis in vivo
Role of Zeb2 in T-Cell Acute Lymphoblastic Leukaemia (T-ALL) Initiation and
Progression
1
Hassan Bassem
KULeuven
4
320 000
Libert Claude
UGent
4
320 000
Parmentier Marc
4
263 000
Sonveaux Pierre
ULB Erasme
UCL
3
195 000
Struman Ingrid
Vandenabeele Peter
ULg
UGent
4
4
203 000
312 000
Vanderkerken Karin
Van Ginderachter Jo
VUB
VUB
3
4
202 500
256 000
4
2
260 000
160 000
Van Tendeloo Viggo
UGent
De Duve UCL
UA
2
120 000
Verfaillie Catherine
KULeuven
2
181 500
UCL
4
150 000
Van Roy Frans
Van Schaftingen Emile
Vikkula Miikka
Mechanistic analysis of the ATOH1 colorectal cancer tumor suppressor gene and its
interactions with the Wnt signaling pathway
Optimisation of αVβ3 targeted nanobodies for cancer therapy, cancer imaging and
targeted delivery.
Mechanisms of anti-inflammatory and anti-tumoral effects of chemerin and its
receptors
Determination of the involvement and contribution of mitochondrial uncoupling to
epithelial-mesenchymal transition (EMT) and cancer stemness in the context of tumor
metastasis
Impact of microRNA transfer from endothelium to cancer cell in tumor progression
Exploitating necroptosis targeting in cancer therapy: High content screening and
validation
Mechanistic in vitro and in vivo study of new drug combinations in multiple myeloma
Characterization of distinct tumor-associated dendritic cell subsets and their
interaction with myeloid-derived suppressor cells.
Roles of Nanos family members in cancer progression
Metabolite alteration in cancer cells: reevaluation of the function of the p53dependent enzyme TIGAR
Reciprocal cross-talk between human natural killer cells and interleukin-15-cultured
dendritic cells for improved anti-leukemic cytotoxic activity
MAPC-based modulation of the immune/inflammatory mechanisms underlying
bone marrow failure in MDS
Next Generation Sequencing to Identify Novel Pathogenic Variants in a Selected
Series of Inherited and Acquired Tumors
2
Grants 2012
Translationele en klinische onderzoeksprojecten
Begunstigde
Beguin Yves
Bours Vincent
Instituut
ULg
ULg
Duurtijd
(jaren)
3
2
Bedrag in
euro
247 500
210 000
Titel van het project
Molecular imaging of multiple myeloma.
MicroRNA expression and/or gene methylation in tissues and plasma samples as new
prognostic/predictive factors of breast cancer.
Towards improved genetic diagnosis for hereditary breast and ovarian cancer:
evolution and challenges
Claes Kathleen
Matthijs Gert
De Grève Jacques
De Moerloose
Barbara
De Neve Wilfried
UGent
KULeuven
VUB
UZGent
3
250 000
3
210 000
The role of non-coding RNA in juvenile myelomonocytic leukaemia
UGent
3
198 000
Accelerated partial breast irradiation using topographical dose painting in prone
position
Dirix Luc
3
199 500
Molecular Analysis in Circulating Tumour Cells of Predictive Biomarkers for targeting
the PI3K-AKT-mTOR pathway in patients with metastatic breast cancer
Duhoux François
GZA St
Augustinus
UCL
2
210 000
Grégoire Vincent
Haustermans Karin
Lambrechts Diether
UCL
UZ Leuven
KULeuven
4
250 000
2
160 000
UCL
3
48 000
UZBrussel
UGent
ULBErasme
Belgian
Cancer
Registry
3
120 000
Identification of new constitutional genetic alterations in patients with a family
history
of breast cancer
Dose-Painting in radiation oncology treatments: the paradigm of head and neck
squamous cells and prostate adenocarcinomas.
Mutation profiles and targeted treatment options for mismatch repair deficient
tumors
One-step MRI for local, regional and general staging of prostate cancer and
assessment of metastatic response
Phase I/II clinical trial on autologous cancer-testis antigen targeted dendritic cell
immunotherapy (TriMixDC) for patients with inoperable pretreated colorectal cancer
3
210 000
Lecouvet Frédéric
Neyns Bart
Van Criekinge Wim
Van Laethem Jean-Luc
Penninckx Freddy
Study of the variability and improving the quality of rectal cancer staging and therapy
in Belgium
3
Prenen Hans
UZleuven
2
210 000
Schöffski Patrick
UZLeuven
3
210 000
Smitz Johan
Dolmans MarieMadeleine
Sotiriou Christos
UZB
UCL
3
250 000
ULB
Bordet
UCL
1
210 000
3
120 000
UCL
UZLeuven
2
4
160 000
160 000
UZGent
UZGent
3
4
200 000
225 000
Squifflet Jean-Luc
Thissen Jean-Paul
Vandecaveye Vincent
Vandesompele Jo
Vral Anne
Identification of candidate biomarkers of intrinsic and acquired resistance to antiangiogenic agents in metastatic colorectal cancer
Molecular characterisation of ALK and MET activation in patients treated with
crizotinib – can we use it to predict the response?
Human Ovary Preservation Expertise (HOPE)
Understanding sensitivity and resistance to trastuzumab and lapatinib in early stage
HER2-overexpressing breast cancer.
Pilot study of neo-adjuvant treatment with galectin-3 inhibitor, GM-CT-01, to
stimulate anergized anti-cancer T lymphocytes in ovarian cancer
Role of Activin A in human cancer cachexia (ACTICA Study)
Improving non-invasive treatment selection and operability assessment in patients
with ovarian cancer: value of whole body diffusion-weighted MRI
Integrated biology-driven diagnostic and therapeutic management of neuroblastoma
Development of radiosensitivity biomarkers in women candidate to early
mammography screening, and investigation of underlying molecular determinants.
4
Grants 2012
Onderzoeken gericht op asbestgerelateerde kanker – Fundamentele onderzoeksprojecten
Begunstigde
De Wever Olivier
Hoet Peter
Lison Dominique
Instituut
UGent
Duurtijd
(jaren)
2
Bedrag in
euro
148 366
KULeuven
2
150 000
UCL
2
150 000
Titel van het project
Microparticle-encapsulated tumor-environment interactions to capture
disseminated mesothelioma cells
Physico-chemical properties of asbestos and carbon nanotubes associated to genetic
and epigenetic effects. Preventing fibrous hazard by design.
Implication of anti-inflammatory and immunosuppressive responses in the
pathogenesis of asbestos-related mesothelioma
Grants 2012
Onderzoeken gericht op asbestgerelateerde kanker – Translationele en klinische onderzoeksprojecten
Begunstigde
Berneman Zwi
Germonpré Paul
Coolen Johan
Nackaerts Kristiaan
Nawrot Tim
Van Meerbeeck Jan
Nackaerts Kristiaan
Willems Luc
Instituut
UA
Duurtijd
(jaren)
3
Bedrag in
euro
247 800
KUleuven
3
160 000
UZLeuven
Hasselt
University
UZ Gent
UZ Leuven
4
200 000
4
200 000
ULg
2
200 000
Titel van het project
First-line chemoimmunotherapy using Wilms’ tumor protein 1 (WT1)-targeted
dendritic cell vaccinations for resectable malignant pleural mesothelioma
The potential role of anatomical as well as diffusion- and perfusion-weighted MRI in
malignant pleural mesothelioma: diagnosis, staging, follow-up and prognostic value
The epidemiology of malignant mesothelioma in Belgium
MesoBreath2: Breath analysis of pleural mesothelioma patients with Ion Mobility
Spectrometry (IMS), eNose and Gas Chromatography-Mass spectrometry (GC-MS): a
comparative validation study.
The role of TGFβin resistance to malignant pleural mesothelioma chemotherapy:
mechanisms and translational research
5